AbbVie today news: Patent win and Gilgamesh acquisition reinforce revenue outlook amid Humira challenge

Traders Union
All News
Financial News
AbbVie Rises 0.68% to $223.98 Today

Highlights

AbbVie Inc. (ABBV) trades at $223.98, up 0.68%, remaining well above all key moving averages and signaling strong multi-timeframe momentum.
ABBV posted a 6.6% year-over-year revenue increase, secured a Rinvoq patent extension to 2037, and expanded its neuroscience portfolio via the Gilgamesh acquisition.
Technical signals remain bullish with high volatility; probabilities exceed 80% for consolidation in the $222.30–$223.84 range, unless a decisive $225 breakout or sub-$212.11 correction occurs.

Pipeline gains and patent maneuvers offset Humira pressure

ABBV reported a 6.6% year-over-year increase in quarterly revenue, with continued support from strong operating cash flow and a quarterly dividend of $1.64 per share. The company secured a critical patent extension for Rinvoq, delaying generic competition until 2037, and expanded its neuroscience portfolio with the acquisition of Gilgamesh Pharmaceuticals’ lead depression drug. These developments help offset challenges such as Humira’s patent expiry and reinforce ABBV’s product pipeline and revenue stability.

Momentum signals falter as overbought conditions and resistance converge

MACD signals continued upside momentum, while ADX indicates trend strength may be waning. RSI at 72.75 is overbought and CCI is also elevated, with Stoch RSI showing mixed overbought and oversold readings intraday. Bull Power (BBP) favors buyers, but several oscillators caution that the price may be stretched. Strong dynamic support levels lie at the Ichimoku Kijun line near $212.11 and the MA-50 at $202.82, while today’s price action near the high of the $221.57 to $225.10 range highlights high intraday volatility and persistent strength.

Sideways range likely as bullish bias dominates near-term outlook

For the next five trading days, ABBV is likely to consolidate sideways near its current highs, trading within a $222.30 to $223.84 range. The probability of further price increases is very high (over 80%) based on bullish weekly trend indicators. If prices decisively break above $225, new highs could follow, but an exhaustion of momentum with a drop below $212.11 would signal short-term correction risk.

Anton Kharitonov, expert at Traders Union, notes that while ABBV’s strong price action and robust fundamentals—such as the Rinvoq patent extension and strategic acquisitions—provide some near-term support, several overbought technical indicators and waning momentum signal heightened caution. He sees consolidation or a shallow pullback as the most likely scenario, given elevated RSI and mixed readings from oscillators. Kharitonov emphasizes risk management if ABBV drops below $212.11, as this would confirm short-term weakness. "Base case remains sideways to slightly up, but until price decisively conquers $225, I remain cautious—no clear breakout setup yet."

Previously it was noted that AbbVie was expected to consolidate between resistance and support levels, with over an 80% chance of further upside in the near term. The analysis highlighted ongoing bullish momentum and a rangebound trading just below recent highs as the most likely scenario.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.